Tbo-filgrastim

N/A

Report date: 2026/05/26 20:00:28

Base Information

Drug NameTbo-filgrastim
Drug Alias Name非格司亭Filgrastimum (Teva)Filgrastim ratiopharm非拉司亭Short-acting G-CSF +[19] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar
Mechanisms of ActionColony stimulating factor 3 receptor agonists
TargetsColony stimulating factor 3 receptor
Therapy Area/IndicationsNeutropeniaHematopoietic stem cell transplantation (HSCT)
Global Approved IndicationsNeutropenia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2008/09/15
Country/TerritoryBulgariaUnited StatesUkraine +[10] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesTeva
China Registration ClassN/A

Develop Information

Active CompaniesSicor Biotech UabSidney Kimmel Cancer Center At Thomas Jefferson UniversityTeva Pharmaceutical Industries Ltd +[5] 
Inactive CompaniesTeva Branded Pharmaceutical Products R&D Inc
Active IndicationsNeutropeniaHematopoietic stem cell transplantation (HSCT)
Inactive IndicationsN/A

Other Information

ATC CodeL03AA02
Related LinksDrugBankKEGG